Chronic kidney disease (CKD) affects more than 1 in 10 Americans and is a major public health problem, both in terms of disease burden and health expenditure as it can lead to kidney failure and eventual need for dialysis or kidney transplantation. Currently, there are no specific therapies for CKD that can prevent the progression into end-stage renal disease and kidney failure. We have shown that communication between two different cell types in the kidney in response to injury is critical to trigger disease progression. There is very little known about this type of cell-to-cell communication; however, we have recently identified specific molecules that could be affecting the physical resilience of kidney cells. In this project, we propose to examine this new communication paradigm and validate these promising findings, using state-of-the-art nanotechnology and patient-derived stem cells. This approach will allow us to explore the specific biological function of each cell type and develop targeted therapeutics. The proposed studies will help validate the cause and timing of key events for each cell type during disease development and provide a better understanding of cell communication with the long-term objective to develop new and more effective therapies for this devastating disease.
|Effective start/end date||1/09/20 → 1/09/20|
- U.S. Army: $1,238,440.00